NORCROSS, Ga., Oct. 14, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ: GALT), the main developer of therapeutics that focus on galectin proteins, introduced right this moment the Company can be presenting at two upcoming conferences.
On October 17, 2022, administration will current in the H.C. Wainwright sixth Annual NASH Investor Conference. Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will ship a company presentation on Monday, October 17, 2022 at 12:00 PM ET. A stay webcast of the dialogue can be out there at this hyperlink in addition to via the investor relations part of the Company’s web site at www.galectintherapeutics.com.
Also, on October 20, 2022, Dr. Boudes is presenting on the Discovery on Target convention in Boston, MA. Dr. Boudes presentation is titled “Innovating in NASH Cirrhosis: Belapectin, a Galectin-3 Inhibitor for Preventing Esophageal Varices in Patients with NASH Cirrhosis” and is a part of Cambridge Healthtech Institute’s 4th annual NASH and Fibrosis convention.
About Belapectin
Belapectin is a posh carbohydrate drug that targets galectin-3, a vital protein in the pathogenesis of NASH and fibrosis. Galectin-3 performs a serious function in illnesses that contain scarring of organs, together with fibrotic issues of the liver, lung, kidney, coronary heart and vascular system. Belapectin binds to galectin-3 and disrupts its operate. Preclinical knowledge in animals have proven that belapectin has sturdy remedy results in reversing liver fibrosis and cirrhosis. A Phase 2 research confirmed belapectin could stop the event of esophageal varices in NASH cirrhosis, and these outcomes present the idea for the conduct of the NAVIGATE trial. The NAVIGATE trial (www.NAVIGATEnash.com), titled “A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis,” started enrolling sufferers in June 2020, and is posted on www.clinicaltrials.gov (NCT04365868). Galectin-3 has a major function in most cancers, and the Company has supported a Phase 1b research in mixed immunotherapy of belapectin and KEYTRUDA in superior melanoma and in head and neck most cancers. This trial supplied a powerful rationale for shifting ahead right into a Company-sponsored Phase 2 improvement program, which the corporate is exploring.
About Fatty Liver Disease with Advanced Fibrosis and Cirrhosis
Non-alcoholic steatohepatitis (NASH) has turn out to be a typical illness of the liver with the rise in weight problems and different metabolic illnesses. NASH is estimated to have an effect on up to 28 million folks in the U.S. It is characterised by the presence of extra fats in the liver together with irritation and hepatocyte harm (ballooning) in individuals who eat little or no alcohol. Over time, sufferers with NASH can develop extreme fibrosis, or scarring of the liver, and finally liver cirrhosis. It is estimated that as many as 1 to 2 million people in the U.S. will develop cirrhosis on account of NASH, for which liver transplantation is the one healing remedy out there. Approximately 9,000 liver transplants are carried out yearly in the U.S. There are not any drug therapies permitted for the remedy of liver fibrosis or cirrhosis.
About Galectin Therapeutics
Galectin Therapeutics is devoted to growing novel therapies to enhance the lives of sufferers with continual liver illness and most cancers. Galectin’s lead drug belapectin (previously often known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is straight concerned in a number of inflammatory, fibrotic, and malignant illnesses, for which it has Fast Track designation by the U.S. Food and Drug Administration for NASH with superior fibrosis. The lead improvement program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, probably the most superior type of NASH-related fibrosis. This is the commonest liver illness and one of many largest drug improvement alternatives out there right this moment. Additional improvement packages are in remedy of mixture immunotherapy for superior melanoma and different malignancies. Advancement of those further medical packages is essentially depending on discovering an appropriate associate. Galectin seeks to leverage in depth scientific and improvement experience in addition to established relationships with exterior sources to obtain cost-effective and environment friendly improvement. Additional info is obtainable at www.galectintherapeutics.com.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
Galectin Therapeutics and its related brand is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned identify for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02.
